Cytotoxic activity of daunomycin and adriamycin encapsulated in immunoliposomes against avian myeloblastosis virus-infected cells.
Immunoliposomes were prepared using the antibody raised against the avian myeloblastosis virus envelope glycoprotein, gp80. Adriamycin was encapsulated into immunoliposomes. More drug was delivered into target cells when the drug encapsulated in immunoliposomes was incubated with the cells. The drug encapsulated in immunoliposomes was able to inhibit the RNA synthesis twice more than free drug in the virus-transformed myeloblasts. Pre-treatment of cells with ammonium chloride, reversed the effect of drug encapsulated in immunoliposomes. The drugs encapsulated in immunoliposomes had marginal effect on the RNA synthesis of non-target cells, the yolk sac cells. Colony formation by virus-transformed cells and focus formation by virus-infected yolk sac cells was inhibited significantly by the drug encapsulated in immunoliposomes.
D000643:Ammonium Chloride / Q000494:pharmacology; D000818:Animals; D000914:Antibodies, Viral / Q000008:administration & dosage; D001354:Avian Leukosis Virus / Q000187:drug effects*; D009189:Avian Myeloblastosis Virus / Q000187:drug effects* / Q000276:immunology; D002470:Cell Survival / Q000187:drug effects; D002472:Cell Transformation, Viral; D002478:Cells, Cultured; D003630:Daunorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D004317:Doxorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D008081:Liposomes / Q000008:administration & dosage; D012313:RNA / Q000096:biosynthesis
D000914:Antibodies, Viral; D008081:Liposomes; D000643:Ammonium Chloride; D012313:RNA; D004317:Doxorubicin; D003630:Daunorubicin